Adam Gilbert

Adam Gilbert joined Flagship Pioneering as a Science Partner in 2026. In this role, he builds innovative scientific platforms and companies aimed at expanding treatment options in areas of significant unmet medical need. He also draws on deep knowledge of the biopharma landscape to help advance companies across the Flagship ecosystem.

Prior to Flagship, Adam spent more than 30 years at Pfizer, where he held multiple leadership roles. He led Design and Synthesis Sciences, a platform medicinal chemistry organization focused on translating cutting-edge approaches into validated biology, including covalent inhibition, allosteric GPCR modulation, induced proximity/targeted protein degradation, and vaccine antigen and adjuvant design. His contributions include the discovery of LITFULO™, ABRYSVO™, COMIRNATY™, and emraclidine, helping strengthen Pfizer’s portfolio from early hit generation through clinical advancement. Adam also served as an External Science Accelerator within Pfizer’s Medicine Design organization, partnering with Research Units and Business Development to build collaborations that complemented Pfizer’s internal pipeline. He spearheaded the Pfizer/Triana Biomedicines molecular glue collaboration and co-led the Pfizer/Flagship Pioneering transcription factor initiative with Montai Therapeutics, Valo Health, and Expedition Medicines. In addition, he helped establish collaborations with Atavistik Bio, Circle Pharma, and Menten AI, leveraging advanced approaches such as fragment screening and macrocyclic peptides to pursue challenging biological targets.

Adam earned a Ph.D. in Chemistry from Columbia University and completed a postdoctoral fellowship at the University of Chicago, where he focused on using organometallic reagents to enable novel synthetic transformations. He has authored or co-authored more than 70 publications and is an inventor on more than 35 patents.